EUVIMEDEUVIMED entdecken
MetaanalyseSystematische ÜbersichtOpen Access · CC BY-NC-ND 4.0

Safety and Efficacy of TACE + Lenvatinib in Treating Advanced Hepatocellular Carcinoma: A Systematic Review and Meta- analysis

Di Pan, Haonan Liu, Xiao Ma, Pengfei Qu, Menghan Cao, Xiaobing Qin, Juanjuan Tang, Ronghai Pan, Qingchen Huang, Zhengxiang Han

Journal of Gastrointestinal and Liver Diseases · 2023

DOI: 10.15403/jgld-4729 ↗

Kurz gefasst

Metaanalyse in der Zeitschrift Journal of Gastrointestinal and Liver Diseases, 2023. Verfasst von Di Pan und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, the Affiliated Hospital of Xuzhou Medical University, Jiangsu, China. . 852672828@qq.com. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Chemoembolization, Therapeutic. Die Arbeit wurde bisher 7-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims: To compare the efficacy and safety of transarterial chemoembolization (TACE) + lenvatinib (TACE+L) versus lenvatinib (L) monotherapy in the treatment of advanced hepatocellular carcinoma by a meta-analysis.

Methods

PubMed, Embase, the Cochrane Library, CNKI, VIP e-Journals Database, and Wanfang Data were systematically searched to collate literature comparing TACE+L with L alone for the treatment of advanced liver cancer. The literature search, quality assessment, and data extraction were performed independently by two reviewers. The Stata 16 software package was used to process and analyze the data. We assessed heterogeneity using both I2 and the p-value, performed a publication bias assessment, and conducted a sensitivity analysis.

Results

Five studies were finally included, including one randomized controlled study and four retrospective studies; these involved a total of 1,167 patients, including 523 patients in the TACE+L combination group and 644 patients in the L monotherapy group. In this meta-analysis, the TACE+L group showed a significantly better objective response rate (ORR) (OR=2.54, 95%CI: 1.34 - 4.80) and disease control rate (DCR) compared to the L monotherapy group (OR=2.68, 95%CI: 1.75 - 4.08). The combined group had significantly improved progression-free survival (PFS) (HR=0.47, 95%CI: 0.40 - 0.56) and overall survival (OS) (HR=0.48, 95%CI: 0.39-0.59). In addition, there was no significant difference found in the overall adverse events of any grade between the two groups (OR=1.13, 95%CI: 0.99 - 1.29).

Conclusions

Compared to L alone, TACE+L treatment resulted in better tumor response, better long-term survival, and was accompanied by controllable adverse events.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsChemoembolization, TherapeuticHumansRetrospective StudiesTreatment OutcomeRandomized Controlled Trials as TopicPhenylurea CompoundsQuinolines

Substanzen

lenvatinibPhenylurea CompoundsQuinolines

Autor:innen und Institutionen

  • Department of Oncology, the Affiliated Hospital of Xuzhou Medical University, Jiangsu, China. . 852672828@qq.com.
  • Department of Oncology, the Affiliated Hospital of Xuzhou Medical University, Jiangsu, China. why974300@163.com.
  • Department of Oncology, the Affiliated Hospital of Xuzhou Medical University, Jiangsu, China. 1764112529@qq.com.
  • Department of Gastroenterology, The second Affiliated Hospital of Xuzhou Medical University, Jiangsu, China. qupengfei1678@163.com.
  • Department of Oncology, the Affiliated Hospital of Xuzhou Medical University, Jiangsu, China. caomenghan163@qq.com.
  • Department of Oncology, the Affiliated Hospital of Xuzhou Medical University, Jiangsu, China. qinxiaobing@163.com.

Zitieren

APA

Pan, D., Liu, H., Ma, X., Qu, P., Cao, M., Qin, X., Tang, J., Pan, R., Huang, Q., & Han, Z. (2023). Safety and Efficacy of TACE + Lenvatinib in Treating Advanced Hepatocellular Carcinoma: A Systematic Review and Meta- analysis. Journal of Gastrointestinal and Liver Diseases. https://doi.org/10.15403/jgld-4729

Vancouver

Pan D, Liu H, Ma X, Qu P, Cao M, Qin X, et al. Safety and Efficacy of TACE + Lenvatinib in Treating Advanced Hepatocellular Carcinoma: A Systematic Review and Meta- analysis. Journal of Gastrointestinal and Liver Diseases. 2023. doi:10.15403/jgld-4729

BibTeX
@article{Pan2023,
  author = {Pan, Di and Liu, Haonan and Ma, Xiao and Qu, Pengfei and Cao, Menghan and Qin, Xiaobing and Tang, Juanjuan and Pan, Ronghai and Huang, Qingchen and Han, Zhengxiang},
  title = {Safety and Efficacy of TACE + Lenvatinib in Treating Advanced Hepatocellular Carcinoma: A Systematic Review and Meta- analysis},
  journal = {Journal of Gastrointestinal and Liver Diseases},
  year = {2023},
  doi = {10.15403/jgld-4729}
}
Kostenlos starten →